Head of Market Access

Kura Oncology, Inc. · San Diego, CA

Company

Kura Oncology, Inc.

Location

San Diego, CA

Type

Full Time

Job Description

Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.

At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.

As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.

To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.

ESSENTIAL JOB FUNCTIONS:

The Executive Director, Market Access will be a key member of Kura Oncology’s Commercial Leadership Team and will be responsible for developing, implementing, and managing all aspects of the US market access strategy, pricing, reimbursement, patient services & hub, and engagement strategy across key customer segments.

  • Reporting to the Chief Commercial Officer, the Executive Director, Market Access will develop and drive the execution of the Kura Oncology market access strategy and operations through oversight of our payer, distributor, patient access, market access strategy, access marketing and pricing & contracting functions.
  • Provide co-stewardship of the Commercial function as a member of the Commercial Leadership Team to build and advance the Kura Commercial vision, talent development, capabilities, and operations.
  • Recruit, lead, motivate, develop, and retain a team of highly skilled market access professionals.
  • Ensure Market Access team is working effectively with cross-functional commercial partners including Marketing, Sales, Operations and Analytics to ensure integration of relevant stakeholder needs, business priorities and market dynamics into integrated business planning activities.
  • Partner with Commercial Insights & Analytics and Sales Operations to refine and manage the channel-based data flows necessary to understand the business, track key trends and performance metrics, and identify opportunities for continued improvement.
  • Lead the development and execution of high-quality HEOR strategies to achieve optimal reimbursement and access for Kura portfolio.
  • Partner with Marketing, HEOR & Medical Affairs to develop product value propositions, evidence generation plans, messaging, and supporting economic analyses/model.
  • Lead the development, execution and ongoing management of all patient service programs and support and hub.
  • Support field-based account management team responsible for payers, specialty pharmacies/distributors, GPOs, state governments and others to create competitive advantage for Kura Oncology and drive patient and business value.
  • Provide guidance to the Kura Oncology Leadership Team on emerging trends, market dynamics, federal and state policy and implications for our business and patients.
  • Work closely with Finance, Legal, Commercial Operations and Analytics to strengthen data strategy and manage data contracts with channel partners to enable sales tracking, revenue recognition, government price reporting, and rebate adjudication and payment.
  • Apply expertise on market access-related matters as part of pipeline planning for early development programs.
  • Monitor and assess US policy and market access environment changes and analyze impact on Kura Oncology’s portfolio, and provides strategic market access input into global development strategies.
  • Develop and drive company government affairs priorities to ensure patient access to current and future therapies.

JOB SPECIFICATIONS:

  • BS/BA degree in business or related discipline with 15+ years’ experience in market access or other commercial roles, or MBA with 10+ years’ experience
  • 5+ years of experience leading market access strategy, key account management across key access stakeholders, field reimbursement, pricing, HEOR and patient HUB services, with a focus in Oncology
  • In-depth, hands-on experience, expertise, and relationships within the US payer landscape in both public and private segments (Deep US & Global market access expertise preferred)
  • Launch experience in Oncology oral therapies administered through the medical benefit (hematology preferred)
  • Demonstrated ability to have the managerial courage to make and stand by difficult decisions.
  • Experience building and leading teams and self in high growth, fast paced environments.
  • Highly skilled in influencing cross-functional teams, including interfacing with key internal and external stakeholders and with scientific and commercial functions.
  • Ability to garner the trust and confidence of the organization from your direct team to the senior leadership team.
  • Exceptional communication skills: equally effective in front of field teams as you are in front of the senior leadership and Board of Directors

The base range for a Head of Market Access is $265,000 - $315,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus


Kura’s Values that are used for candidate selection and performance assessments:

  • We work as one for patients
  • We are goal-focused and deliver with excellence
  • We are science-driven courageous innovators
  • We strive to bring out the best in each other and ourselves

The Kura Package

  • Career advancement/ development opportunities
  • Competitive comp package
  • Bonus
  • 401K + Employer contributions
  • Generous stock options
  • ESPP Plan
  • 20 days of PTO to start
  • 18 Holidays  (Including Summer & Winter Break)
  • Generous Benefits Package with a variety of plans available with a substantial employer match
  • Paid Paternity/Maternity Leave
  • In-Office Catered lunches
  • Home Office Setup
  • Lifestyle Spending Stipend
  • Commuter Stipend (Boston Office)
  • Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!

Kura Oncology is a clinical-stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. The company’s diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s approach to drug development is focused on rapidly translating novel science into life-saving medicines. Our goal is to help patients with cancer lead better, longer lives. Kura Oncology has offices in San Diego, California, and Boston, Massachusetts.

Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors. For additional information, please visit Kura’s website at www.kuraoncology.com. 

Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status. 

Apply Now

Date Posted

10/03/2023

Views

12

Back to Job Listings Add To Job List Company Profile View Company Reviews
Neutral
Subjectivity Score: 0.5